Secretome vs. PRP Injections for Hair Density and Growth in Androgenetic Alopecia Patients

ConditionAndrogenetic Alopecia

Trial statusRecruiting

Trial phasePhase 1, Phase 2

Trial typeInterventional

Biological sexAll

Age25-59

SponsorPT. Prodia Stem Cell Indonesia

About this trial

This study aims to compare the effectiveness of secretome injection and intradermal platelet-rich plasma (PRP) injection on hair density and the terminal-to-vellus hair ratio in patients with androgenetic alopecia at Prof. Dr. I.G.N.G. Ngoerah General Hospital.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Male patients with androgenetic alopecia, aged 25 to 59 years, with clinical presentation consistent with Hamilton-Norwood grades II to VI, seeking treatment at the Dermatology and Venereology Outpatient Clinic of Prof. Dr. I.G.N.G. Ngoerah General Hospital.

Female patients with androgenetic alopecia, aged 25 to 59 years, with clinical presentation consistent with Ludwig grades I to III, seeking treatment at the Dermatology and Venereology Outpatient Clinic of Prof. Dr. I.G.N.G. Ngoerah General Hospital.

Female patients who are not currently pregnant or breastfeeding.

Patients who have discontinued anti-androgen medication and minoxidil for at least 1 month prior to the procedure.

Disqualifiers

Participants who are unable to speak or understand Indonesian and/or are unwilling to provide written informed consent.

Patients presenting with types of hair loss other than androgenetic alopecia.

Patients currently undergoing therapy with 5-alpha reductase inhibitors.

Patients who have received intradermal corticosteroid injections to the scalp within at least 6 months prior to the study.

Trial design

Design model

Parallel

Treatments tested in this trial

Secretome
Biological/Vaccine
UC-MSC secretome was injected intradermally into the scalp at the alopecia site, with injections spaced 1 cm apart and administered every 2 weeks for 8 weeks
Platelet-Rich Plasma (PRP) Injections
Biological/Vaccine
The centrifuged plasma solution was injected intradermally into the scalp at the alopecia site, with 0.1 ml per injection point spaced 1 cm apart, administered every 2 weeks for 8 weeks

Treatment groups

40 Participants

are divided into 2 treatment groups

Group A: UC-MSC SecretomeExperimental treatment 1 intervention

Group B: Platelet-Rich PlasmaExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

Terminal-to-Vellus Hair Ratio

The ratio of terminal hair (thick, pigmented hair, diameter \>40 micrometer) to vellus hair (fine hair, diameter \<30 micrometer) in areas of androgenetic alopecia

Time frame

Baseline (before treatment), post-intervention (at 8 weeks), and during follow-up visits (months 3, 6, and 9)

Hair density

The number of hairs per specific scalp area was measured in hairs/cm²

Time frame

Baseline (before treatment), post-intervention (at 8 weeks), and during follow-up visits (months 3, 6, and 9)

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

PT. Prodia Stem Cell Indonesia

Lead sponsor

RS Prof. Dr. I.G.N.G Ngoerah

Collaborator

Source ClinicalTrials.gov

Apply now